BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352]
URL: https://www.wjgnet.com/1007-9327/full/v7/i5/352.htm
Number Citing Articles
1
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancerCritical Reviews in Oncology/Hematology 2021; 160: 103234 doi: 10.1016/j.critrevonc.2021.103234
2
Paul Noordhuis, Adrianus C. Laan, Kasper van de Born, Richard J. Honeywell, Godefridus J. Peters. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell LinesInternational Journal of Molecular Sciences 2019; 20(15): 3619 doi: 10.3390/ijms20153619
3
Jan P. van Meerbeeck, Gerrit Jansen, Elisa Giovannetti, Godefridus J. Peters. Aminopeptidase antibodies in mesothelioma: new wine deserves new sacksEuropean Respiratory Journal 2018; 51(5): 1800817 doi: 10.1183/13993003.00817-2018
4
Shaoxin Cai, Xuefei Cheng, Yi Liu, Zhizun Lin, Wei Zeng, Changshun Yang, Lihang Liu, Ozor Anthony Chukwuebuka, Weihua Li. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancerExperimental Cell Research 2018; 367(1): 37 doi: 10.1016/j.yexcr.2018.02.028
5
Jiang Du, Xiupeng Zhang, Haijing Zhou, Yuan Miao, Yong Han, Qiang Han, Enhua Wang. Alex3 suppresses non–small cell lung cancer invasion via AKT/Slug/E-cadherin pathwayTumor Biology 2017; 39(7): 101042831770144 doi: 10.1177/1010428317701441
6
Shasha Yin, Liu Liu, Charles Brobbey, Viswanathan Palanisamy, Lauren E. Ball, Shaun K. Olsen, Michael C. Ostrowski, Wenjian Gan. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesisNature Communications 2021; 12(1) doi: 10.1038/s41467-021-23833-2
7
Sven de Mey, Inès Dufait, Mark De Ridder. Radioresistance of Human Cancers: Clinical Implications of Genetic Expression SignaturesFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.761901
8
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancerBreast Cancer Research 2020; 22(1) doi: 10.1186/s13058-020-01286-7
9
Liu Liu, Xiaoming Dai, Shasha Yin, Pengda Liu, Elizabeth G. Hill, Wenyi Wei, Wenjian Gan. DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathwayScience Signaling 2022; 15(715) doi: 10.1126/scisignal.abh2290
10
Mahendra Jadhao, Eing-Mei Tsai, Ho-Chun Yang, Yih-Fung Chen, Shih-Shin Liang, Tsu-Nai Wang, Yen-Ni Teng, Hurng-Wern Huang, Li-Fang Wang, Chien-Chih Chiu. The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROSAntioxidants 2021; 10(6): 949 doi: 10.3390/antiox10060949
11
Isabell Götting, Verena Jendrossek, Johann Matschke. A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy ResistanceInternational Journal of Molecular Sciences 2020; 21(22): 8563 doi: 10.3390/ijms21228563
12
Fatemeh Ghaemimanesh, Majid Mehravar, Saeideh Milani, Ensieh M. Poursani, Kioomars Saliminejad. The multifaceted role of sortilin/neurotensin receptor 3 in human cancer developmentJournal of Cellular Physiology 2021; 236(9): 6271 doi: 10.1002/jcp.30344
13
Afsane Bahrami, Majid Khazaei, Soodabeh Shahidsales, Seyed Mahdi Hassanian, Malihe Hasanzadeh, Mina Maftouh, Gordon A. Ferns, Amir Avan. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and ProgressJournal of Cellular Biochemistry 2018; 119(1): 213 doi: 10.1002/jcb.26136
14
Zechen Zhao, Weiming Chu, Yang Zheng, Chao Wang, Yuemei Yang, Teng Xu, Xueming Yang, Wei Zhang, Xu Ding, Gang Li, Hongchuang Zhang, Junbo Zhou, Jinhai Ye, Heming Wu, Xiaomeng Song, Yunong Wu. Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathwayCell Communication and Signaling 2021; 19(1) doi: 10.1186/s12964-021-00800-4
15
Abdulmelik Aytatli, Neslisah Barlak, Fatma Sanli, Hasan Onur Caglar, Betul Gundogdu, Arzu Tatar, Michael Ittmann, Omer Faruk Karatas. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancerCellular Oncology 2021;  doi: 10.1007/s13402-021-00645-6
16
Franziska E. Marquard, Manfred Jücker. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancerBiochemical Pharmacology 2020; 172: 113729 doi: 10.1016/j.bcp.2019.113729
17
Afsane Bahrami, Majid Khazaei, Malihe Hasanzadeh, Soodabeh ShahidSales, Mona Joudi Mashhad, Marjaneh Farazestanian, Hamid Reza Sadeghnia, Majid Rezayi, Mina Maftouh, Seyed Mahdi Hassanian, Amir Avan. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and ProgressJournal of Cellular Biochemistry 2018; 119(3): 2460 doi: 10.1002/jcb.25950
18
Navid Sobhani, Giandomenico Roviello, Silvia P. Corona, Maurizio Scaltriti, Anna Ianza, Marina Bortul, Fabrizio Zanconati, Daniele Generali. The prognostic value of PI3K mutational status in breast cancer: A meta‐analysisJournal of Cellular Biochemistry 2018; 119(6): 4287 doi: 10.1002/jcb.26687
19
Nader Akbari Dilmaghani, Ava Safaroghli‐Azar, Atieh Pourbagheri‐Sigaroodi, Davood Bashash. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapiesIUBMB Life 2021; 73(4): 618 doi: 10.1002/iub.2446
20
Charu Guleria, Vanita Suri, Rakesh Kapoor, Ranjana Walker Minz, Ritu Aggarwal. Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma developmentGynecologic Oncology 2019; 155(1): 151 doi: 10.1016/j.ygyno.2019.07.023
21
Jim Moselhy, Suman Suman, Mohammed Alghamdi, Balaji Chandarasekharan, Trinath P. Das, Alatassi Houda, Murali Ankem, Chendil Damodaran. Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate CancerNeoplasia 2017; 19(6): 451 doi: 10.1016/j.neo.2017.04.005
22
Sara M. Maloney, Camden A. Hoover, Lorena V. Morejon-Lasso, Jenifer R. Prosperi. Mechanisms of Taxane ResistanceCancers 2020; 12(11): 3323 doi: 10.3390/cancers12113323
23
Parastoo Modarres, Farzaneh Mohamadi Farsani, Amir Abas Nekouie, Sadeq Vallian. Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AMLScientific Reports 2021; 11(1) doi: 10.1038/s41598-021-91864-2
24
Kazuo Tomita, Manabu Fukumoto, Katsuhiko Itoh, Yoshikazu Kuwahara, Kento Igarashi, Taisuke Nagasawa, Masatoshi Suzuki, Akihiro Kurimasa, Tomoaki Sato. MiR-7-5p is a key factor that controls radioresistance via intracellular Fe2+ content in clinically relevant radioresistant cellsBiochemical and Biophysical Research Communications 2019; 518(4): 712 doi: 10.1016/j.bbrc.2019.08.117
25
Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti, Patrizia Diana. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)Cancers 2021; 13(17): 4389 doi: 10.3390/cancers13174389
26
Yufei Tang, Shaoqi Zong, Hailun Zeng, Xiaofeng Ruan, Liting Yao, Susu Han, Fenggang Hou. MicroRNAs and angiogenesis: a new era for the management of colorectal cancerCancer Cell International 2021; 21(1) doi: 10.1186/s12935-021-01920-0
27
Godefridus J. Peters. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies2020; : 1 doi: 10.1016/B978-0-12-819937-4.00001-7
28
Christopher E. Eyermann, John D. Haley, Evguenia M. Alexandrova. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancerCell Death & Disease 2021; 12(1) doi: 10.1038/s41419-021-03414-3
29
Annette A. van Zweeden, Roza C.M. Opperman, Richard J. Honeywell, Godefridus J. Peters, Henk M.W. Verheul, Hans J. van der Vliet, Dennis Poel. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapyCancer Treatment and Research Communications 2021; 27: 100371 doi: 10.1016/j.ctarc.2021.100371
30
C. G. Da Silva, Godefridus J. Peters, Ferry Ossendorp, Luis J. Cruz. The potential of multi-compound nanoparticles to bypass drug resistance in cancerCancer Chemotherapy and Pharmacology 2017; 80(5): 881 doi: 10.1007/s00280-017-3427-1
31
Cristina Cuesta, Cristina Arévalo-Alameda, Esther Castellano. The Importance of Being PI3K in the RAS Signaling NetworkGenes 2021; 12(7): 1094 doi: 10.3390/genes12071094
32
Gopal P. Pathak, Rashmi Shah, Barry E. Kennedy, J. Patrick Murphy, Derek Clements, Prathyusha Konda, Michael Giacomantonio, Zhaolin Xu, Isabel R. Schlaepfer, Shashi Gujar. RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in CancersMolecular Therapy 2018; 26(8): 2019 doi: 10.1016/j.ymthe.2018.05.026
33
Robin Van Den Borg, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti, Godefridus J. Peters. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirineExpert Review of Anticancer Therapy 2019; 19(6): 461 doi: 10.1080/14737140.2019.1624530
34
Hai Huang, Jun-Koo Yi, Su-Geun Lim, Sijun Park, Haibo Zhang, Eungyung Kim, Soyoung Jang, Mee-Hyun Lee, Kangdong Liu, Ki-Rim Kim, Eun-Kyong Kim, Youngkyun Lee, Sung-Hyun Kim, Zae-Young Ryoo, Myoung Ok Kim. Costunolide Induces Apoptosis via the Reactive Oxygen Species and Protein Kinase B Pathway in Oral Cancer CellsInternational Journal of Molecular Sciences 2021; 22(14): 7509 doi: 10.3390/ijms22147509